Naveen Pemmaraju/X
Sep 8, 2025, 07:11
Naveen Pemmaraju at SOHO 2025: Presenting Effects of Rusfertide for Polycythemia Vera on Behalf of VERIFY Colleagues
Naveen Pemmaraju, Executive Director-Cancer Medicine for MDACC Cancer Network, shared on X:
”SOHO 2025
Thanks to Society of Hematologic Oncology for the opportunity to present, on behalf of VERIFY colleagues, our randomized phase 3 results hepcidin mimetic Rusfertide for patients with Polycythemia Vera (PV).”
More from SOHO 2025 featured in Hemostasis Today.
-
Feb 26, 2026, 15:58Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
-
Feb 26, 2026, 15:51Augustina Isioma Ikusemoro: The Real Miracle in Trauma Care Happens Behind the Scenes
-
Feb 26, 2026, 15:42Jim Hoffman։ Targeting NETosis to Improve Perfusion and Reduce Thrombosis in AMI
-
Feb 26, 2026, 15:40Elvira Grandone: ISTH Launches An International Survey to Capture Real-World Practice of Pregnancy Anemia
-
Feb 26, 2026, 15:39Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
-
Feb 26, 2026, 15:37Nayab Ahmed: Main Reasons for Washing Platelet-Rich Plasma
-
Feb 26, 2026, 15:36Robert Negrin Shares His Outlook for the Year Ahead as ASH President
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke